SciSparc has initiated a clinical trial using its proprietary therapy, SCI-210, at Soroka Medical Center, Israel, targeting Autism Spectrum Disorder symptoms in children. SciSparc’s novel SCI-210 therapy is not only a medication based on CBD; it is also a unique combination of cannabidiol and SciSparc’s proprietary Palmitoylethanolamide, aimed to ease the symptoms of ASD. Over a period of 20 weeks, the trial will enroll 60 participants between the ages of 5-18 years old to scientifically measure how SCI-210 compares to standard CBD treatment in managing ASD symptoms. The trial is structured as a randomized, double-blind, placebo-controlled trial.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SPRC:
- New Hope for Children: SciSparc’s patented CBD- Enhanced Solution for Autism Spectrum Disorder
- SciSparc signs non-binding LOI to merge with vehicle importer company in Israel
- SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel
- SciSparc announces results from its Phase II trial on SCI-110
- SciSparc Celebrates Major Breakthrough: Positive Results Show its Treatment has a Remarkable Impact on Alzheimer’s Agitation